Followers | 3344 |
Posts | 84628 |
Boards Moderated | 6 |
Alias Born | 10/05/2005 |
Sunday, May 26, 2019 10:00:19 PM
Zacks
Zacks Equity Research
,Zacks•May 20, 2019
Investors in Sorrento Therapeutics, Inc. SRNE need to pay close attention to the stock based on moves in the options market lately. That is because the Jun 21, 2019 $5.00 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?
Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?
Clearly, options traders are pricing in a big move for Sorrento shares, but what is the fundamental picture for the company? Currently, Sorrento is a Zacks Rank #3 (Hold) in the Medical - Biomedical and Genetics industry that ranks in the Top 32% of our Zacks Industry Rank. Over the last 60 days, no analysts have increased their earnings estimate for the current quarter, while one has revised the estimates downward. The net effect has taken our Zacks Consensus Estimate for the current quarter from a loss of 30 cents per share to a loss of 35 cents in that period.
Given the way analysts feel about Sorrento right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
Lets exchange member marks and exchange market moving information today!
All my posts are strictly my opinion only! Please do your own DD.
Recent SRNE News
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 09:31:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:15:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 01:51:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2023 09:25:07 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/07/2023 08:15:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2023 10:01:54 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 10:26:26 AM
- Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patients with locally advanced/metastatic solid tumors at the A • GlobeNewswire Inc. • 06/05/2023 01:00:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM